Article Sidebar

PDF
Date Published: 26/05/2023
Abstract Views: 218
Views PDF: 153
DOI: https://doi.org/10.51298/vmj.v526i1B.5411
Issue
Vol. 526 No. 1B (2023)
Section
Các bài báo
How to Cite
Lê, T. D. ., Phạm , T. N. ., & Thân , V. S. . (2023). TRANSARTERIAL BLEOMYCIN EMBOLIZATION FOR HEPATIC HEMANGIOMA. Vietnam Medical Journal, 526(1B). https://doi.org/10.51298/vmj.v526i1B.5411

TRANSARTERIAL BLEOMYCIN EMBOLIZATION FOR HEPATIC HEMANGIOMA

Thanh Dũng Lê1,2,3,, Thế Nghĩa Phạm 3, Văn Sỹ Thân 1
1 Viet Duc hospital
2 VNU Hanoi-University of Medicine and Pharmacy
3 Hanoi medical university

Main Article Content

Abstract

Objective: To evaluate the short-term effectiveness of endovascular intervention (TAE) with lipiodol–bleomycin (LBE) mixture for large liver hemangiomas. Methods: Retrospective study on 16 patients with large liver hemangiomas who underwent TAE with LBE from January 2022 to December 2022 at Viet Duc Friendship Hospital. The patients were followed up by injection CT or MRI at 1 and 6 months, respectively, after TAE. Results: mean age of patients was 55.31 ± 8.5 years old. The largest tumor diameter before and after the intervention was 71.56 ± 20.11 mm and 61.31 ± 24.36 mm, in which the largest diameter of the remaining enhancement was 28.62 ± 25.96 mm; the difference was statistically significant (p < 0.001). TAE was technically successful in all patients without major complications. Improvement in abdominal symptoms was noted in all cases (100%). Conclusion: TAE with LBE is a safe and effective method for symptomatic and/or large liver hemangiomas. More studies with larger sample sizes and comparisons are needed to evaluate the safety and effectiveness of this method.

Article Details

Keywords

large liver hemangioma, transarterial embolization, bleomycin

References

1. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005;39(5):401–12.
2. Giavroglou C, Economou H, Ioannidis I. Arterial embolization of giant hepatic hemangiomas. Cardiovasc Intervent Radiol 2003; 26:92–6.
3. Erdogan D, Busch OR, Van Delden OM, Bennink RJ, Ten Kate FJ, Gouma DJ, et al. Management of liver hemangiomas according to size and symptoms. J Gastroenterol Hepatol 2007;22(11):1953–8.
4. Ribeiro Jr MAF, Papaiordanou F. Gonc\c alves, JM, et al. (2010) Spontaneous Rupture of Hepatic Hemangiomas: A Review of the Literature. World J Hepatol n.d.;2:428–33.
5. Ho H-Y, Wu T-H, Yu M-C, Lee W-C, Chao T-C, Chen M-F. Surgical management of giant hepatic hemangiomas: complications and review of the literature. Chang Gung Med J 2012;35(1):70–8.
6. Malagari K, Alexopoulou E, Dourakis S, Kelekis A, Hatzimichail K, Sissopoulos A, et al. Transarterial embolization of giant liver hemangiomas associated with Kasabach-Merritt syndrome: a case report. Acta Radiol 2007; 48(6):608–12.
7. BENNETT JM, REICH SD. Drugs five years later: bleomycin. Ann Intern Med 1979;90(6):945–8.
8. Oikawa T, HIROTANI K, OGASAWARA H, KATAYAMA T, ASHINOFUSE H, SHIMAMURA M, et al. Inhibition of angiogenesis by bleomycin and its copper complex. Chem Pharm Bull (Tokyo) 1990;38(6):1790–2.
9. Chen Y, Li Y, Zhu Q, Zeng Q, Zhao J, He X, et al. Fluoroscopic intralesional injection with pingyangmycin lipiodol emulsion for the treatment of orbital venous malformations. Am J Roentgenol 2008;190(4):966–71.
10. Zeng Q, Li Y, Chen Y, Ouyang Y, He X, Zhang H. Gigantic cavernous hemangioma of the liver treated by intra-arterial embolization with pingyangmycin-lipiodol emulsion: a multi-center study. Cardiovasc Intervent Radiol 2004;27:481–5.